Tenet Healthcare Corporation — Q3 2022 Form 10-Q
Business context and period. Unaudited results cover the quarter and nine months ended September 30, 2022, compared with the same 2021 periods. Tenet operates Hospital Operations, Ambulatory Care (USPI) and Conifer. At quarter-end it operated 61 hospitals; USPI had interests in 440 ambulatory surgery centers and 24 surgical hospitals; Conifer served approximately 670 clients.
Financial results and liquidity
- Revenue: Q3 net operating revenue was $4.801 billion, down 1.9%. Nine-month revenue was $14.184 billion, down 3.0%.
- Profit: Q3 operating income was $596 million versus $1.014 billion; net income attributable to Tenet common shareholders was $131 million versus $449 million. Nine-month operating income was $1.797 billion versus $2.120 billion; common-shareholder net income was $309 million versus $665 million. Diluted EPS was $1.16 in Q3 and $2.81 for nine months, compared with $4.12 and $6.13, respectively.
- Margins and adjusted EBITDA: GAAP operating margin was 12.4% in Q3 versus 20.7%, and 12.7% for nine months versus 14.5%. Adjusted EBITDA, a non-GAAP measure, was $841 million in Q3 versus $855 million (17.5% margin in both periods) and $2.572 billion for nine months versus $2.466 billion (18.1% versus 16.9%).
- Cash flow: Nine-month operating cash flow was $662 million versus $1.211 billion. Capital expenditures were $472 million, making operating cash flow less capital expenditures $190 million, compared with $857 million in 2021. Cash declined to $1.208 billion from $2.364 billion at year-end 2021.
- Debt and liquidity: Long-term debt was $15.093 billion, including current maturities, and cash was $1.208 billion. Net debt to trailing 12-month Adjusted EBITDA was 3.87x. The company had no revolver borrowings and $1.5 billion available under its revolving facility; it reported compliance with credit-facility covenants. The $1.5 billion revolver matures in March 2027.
- Other metrics: Accounts receivable were $2.826 billion; AR days were 58, above Tenet’s target of less than 55. Current liabilities were $4.276 billion and current assets were $5.998 billion.
Material changes versus prior period
- Hospital Operations revenue fell 6.3% in Q3 before intersegment eliminations, primarily reflecting the Miami hospital sale, lower patient volumes and lower COVID-related acuity; commercial rate increases partly offset the decline. Same-hospital Q3 admissions declined 5.3% and outpatient visits declined 6.9%.
- Ambulatory Care revenue grew 21.0% in Q3 and 17.2% for nine months, supported principally by acquisitions, with same-facility revenue also increasing. Consolidated cases rose 12.7% in Q3.
- Conifer revenue increased 6.1% in Q3 and 5.0% for nine months, reflecting rate increases and new business.
- The prior-year comparisons include a $409 million gain on the August 2021 sale of the Miami hospitals; there were no comparable facility-sale gains in 2022. This materially elevates prior-year operating income and earnings.
- Cash flow was affected by repayment or recoupment of $880 million of Medicare advances in the first nine months of 2022; no such advance liability remained at September 30, 2022. Nine-month financing activity included redemption or repurchase of $2.572 billion of note principal.
Outlook, commentary, risks and unusual items
- Management forecast 2022 continuing-operations capital expenditures of approximately $725 million to $775 million. It described $250 million annually as a baseline investment intention for ambulatory acquisitions and de novo facilities, not a formal earnings forecast.
- Management estimated the final FY2023 Medicare inpatient payment changes could increase its annual Medicare fee-for-service IPPS payments by about $55 million. Proposed outpatient and ASC payment effects remained uncertain; the filing estimated hospital outpatient revenue increases of about $21 million under the then-current 340B policy or about $3 million under the anticipated policy. These are estimates, not assured outcomes.
- In April 2022, a cybersecurity incident temporarily disrupted some acute-care operations and involved exfiltration of confidential company and patient information. Tenet estimated an adverse pre-tax impact of approximately $100 million through September, and had received $13 million in related insurance recoveries; the timing and amount of further recovery were uncertain.
- Tenet cited COVID-19 uncertainty, lower patient volumes, staffing shortages and costly contract labor, inflation and supply constraints, payer and reimbursement uncertainty, and possible patient-receivable collectability changes as business risks. Hurricane Ian also adversely affected some ambulatory facilities.
- Unusual charges included $109 million of nine-month losses on early debt extinguishments, $97 million of restructuring, impairment and acquisition-related costs, and a $113 million tax valuation allowance increase related to interest-expense carryforwards. The company also recognized $154 million of grant income for nine months, compared with $53 million in 2021.
- Material matters include an ongoing DOJ investigation of Detroit Medical Center concerning alleged Stark Law, anti-kickback and False Claims Act issues, and other litigation risks. A bankruptcy-related settlement concerning the former Philadelphia hospitals was completed with $22 million of payments in Q3. In October 2022, the board authorized a $1 billion share repurchase program; repurchases are discretionary and not guaranteed.
Key facts investors should verify
- Whether hospital volumes, staffing costs and hospital margins stabilize, and whether Ambulatory Care growth continues beyond acquisition contributions.
- The cash-flow impact of working capital, payer collections, supplemental Medicaid receipts and the completion of Medicare advance recoupments.
- Debt reduction and refinancing capacity, including the effect of the 2030 secured-note issuance and the 3.87x net leverage measure.
- Actual cybersecurity losses and insurance recoveries, and any developments in the Detroit Medical Center investigation or other material claims.
- Whether forecast capital expenditures, reimbursement estimates and the authorized buyback are implemented as described; the filing provides no formal full-year earnings or revenue guidance.